

Your reference Our reference Date

January 12, 2024

Changes to Franklin Templeton Investment Funds ("FTIF") and the Underlying Funds (as defined below)

Zurich International Life Limited

(a company incorporated in the Isle of Man with limited liability)

25-26/F, One Island East 18 Westlands Road Island East, Hong Kong

Website: www.zurich.com.hk

Zurich International Life Limited provides life assurance, investment and protection products and is authorized by the Isle of Man Financial Services Authority.

Registered in the Isle of Man number 20126C.

Registered office: Zurich House, Isle of Man Business Park, Douglas, Isle of Man, IM2 2QZ, British Isles THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. IF IN DOUBT, PLEASE SEEK PROFESSIONAL ADVICE.

We accept full responsibility for the accuracy of the content of this document. Unless otherwise specified herein, capitalized terms used in this letter shall have the meanings assigned to such terms in the Explanatory Memorandum of FTIF dated April 2023 (the "Explanatory Memorandum").

Dear valued customer,

We are writing to let you know about the changes to FTIF and the Underlying Funds. You have invested in at least one of the investment choices corresponding to the Underlying Funds, which are listed in the "Which investment choices are affected?" table below under the column "Name and code of the investment choice".

Which investment choices are affected?

Name and code of the investment choice (Individually, the "Investment Choice"; Collectively, the "Investment Choices")	Name of the corresponding underlying fund (Individually, the "Underlying Fund"; Collectively, the "Underlying Funds")	Applicable scheme (the "Schemes")
ZI Franklin US Government Fund (Code: TCUSD)	Franklin Templeton Investment Funds - Franklin U.S. Government Fund	 DOMUS Futura II Futura III Elite International Bond SUPRA Savings and Investment Plan Vista Vista Retirement Scheme
ZI Templeton BRIC Fund (Code: TFUSD) ZI Templeton Emerging Markets Fund (Code: TBUSD)	Franklin Templeton Investment Funds - Templeton BRIC Fund Franklin Templeton Investment Funds - Templeton Emerging	
ZI Templeton Global Smaller Companies Fund (Code: TAUSD)	Markets Fund Franklin Templeton Investment Funds - Templeton Global Smaller Companies Fund	
ZI Templeton Global Total Return Fund (Code: TDUSD)	Franklin Templeton Investment Funds - Templeton Global Total Return Fund	



	T	1
ZI Franklin Gold and Precious Metals Fund (Code: 6CUSD)	Franklin Templeton Investment Funds - Franklin Gold and Precious Metals Fund	 Futura II Futura III Elite International Bond SUPRA Savings and Investment Plan Vista Vista Retirement Scheme
ZI Franklin MENA USD Fund (Code: GCUSD)	Franklin Templeton Investment Funds - Franklin MENA Fund	
ZI Franklin Mutual Global Discovery Fund (Code: R2USD) ZI Templeton Asian Bond Fund (Code: 4QUSD)	Franklin Templeton Investment Funds - Franklin Mutual Global Discovery Fund Franklin Templeton Investment Funds - Templeton Asian Bond Fund	
ZI Templeton Global Bond fund (Code: TEUSD)	Franklin Templeton Investment Funds - Templeton Global Bond Fund	
Franklin Templeton Investment Funds - Franklin Biotechnology Discovery Fund (Code: USDTC)	Franklin Templeton Investment Funds - Franklin Biotechnology Discovery Fund	International Wealth Account IWA Pacific
Franklin Templeton Investment Funds - Franklin Gold and Precious Metals Fund EUR (Code: HSEUR) Franklin Templeton Investment	Franklin Templeton Investment Funds - Franklin Gold and Precious Metals Fund	
Funds - Franklin Gold and Precious Metals Fund USD (Code: 6BUSD)		
Franklin Templeton Investment Funds - Franklin India Fund (Code: FWUSD)	Franklin Templeton Investment Funds - Franklin India Fund	
Franklin Templeton Investment Funds - Franklin MENA Fund USD (Code: GDUSD)	Franklin Templeton Investment Funds - Franklin MENA Fund	
Franklin Templeton Investment Funds - Franklin Mutual European Fund (Code: FVUSD)	Franklin Templeton Investment Funds - Franklin Mutual European Fund	
Franklin Templeton Investment Funds - Franklin Mutual Global Discovery Fund (Code: Q2USD)	Franklin Templeton Investment Funds - Franklin Mutual Global Discovery Fund	
Franklin Templeton Investment Funds - Franklin Mutual U.S. Value Fund (Code: KYUSD)	Franklin Templeton Investment Funds - Franklin Mutual U.S. Value Fund	
Franklin Templeton Investment Funds - Franklin U.S. Government Fund (Code: ZVUSD)	Franklin Templeton Investment Funds - Franklin U.S. Government Fund	
Franklin Templeton Investment Funds - Templeton Asian Bond Fund (Code: 4PUSD)	Franklin Templeton Investment Funds - Templeton Asian Bond Fund	
Franklin Templeton Investment Funds - Templeton Asian Growth Fund USD (Code: KOUSD)	Franklin Templeton Investment Funds - Templeton Asian Growth Fund	



Franklin Templeton Investment Funds - Templeton Emerging Markets Fund (Code: MMUSD)	Franklin Templeton Investment Funds - Templeton Emerging Markets Fund	
Franklin Templeton Investment Funds - Templeton Global Smaller Companies Fund (Code: MLUSD)	Franklin Templeton Investment Funds - Templeton Global Smaller Companies Fund	
Franklin Templeton Investment Funds - Templeton Global Total Return Fund (Code: PDUSD)	Franklin Templeton Investment Funds - Templeton Global Total Return Fund	

What is happening?

We have been notified by Franklin Templeton Investments (Asia) Limited, as the Hong Kong Representative of FTIF, of the changes set out below which took effect as of August 27, 2023.

1. Updated pre-contractual disclosures of the Franklin Templeton Investment Funds - Franklin Biotechnology Discovery Fund, Franklin Templeton Investment Funds - Templeton Asian Bond Fund and Franklin Templeton Investment Funds - Templeton Global Bond Fund

The pre-contractual disclosures of the Underlying Funds shall be updated to reflect the latest template required to be used pursuant to the Commission Delegated Regulation (EU) 2023/363, which includes two additional questions in relation to investment by the Underlying Funds in fossil gas and/or nuclear energy related to activities that comply with the Taxonomy Regulation.

In addition, the pre-contractual disclosures of the relevant Underlying Fund shall be amended to reflect the following key updates:

(a) The question headed "What investment strategy does this financial product follow?" in the pre-contractual disclosure of the Franklin Templeton Investment Funds - Franklin Biotechnology Discovery Fund shall be revised to include "nuclear weapons" as one of the specific ESG exclusions.

The updated bilingual pre-contractual disclosures for the Underlying Funds are available for download from the Hong Kong Representative of FTIF's website at

https://franklintempletonprod.widen.net/s/jqdp5bk5xt/ftif-sfdr-pre-contractual-disclosure-annexes_hk_en* (English version) and

https://franklintempletonprod.widen.net/s/hv85nxn6tb/ftif-sfdr-pre-contractual-disclosure-annexes_hk_cn^{*} (traditional Chinese version), and they are also available at the office of the Hong Kong Representative of FTIF.

2. Updates to the valuation policy of FTIF

To clarify that the costs incurred in obtaining and maintaining registrations in different countries as well as fees for facilities services and company secretary services are charged to FTIF, item (e) under the paragraph relating to total liabilities in the sub-section headed "VALUATION" in the section headed "ADDITIONAL INFORMATION" of the Explanatory Memorandum shall be updated as follows (with revisions in mark-up):

"(e) all other liabilities of the Company of whatsoever kind and nature except liabilities represented by Shares in the Company. In determining the amount of such liabilities the Company shall take into account all relevant expenses payable by the Company comprising formation expenses, fees and expenses at the accounts, fees payable to the Management Company for the performance of its various services and for those rendered by the Investment Managers and/or investment advisers, the Depositary and local paying agents and permanent representatives in places of registration as well as costs incurred in obtaining and maintaining registrations in different countries, any other agent employed by the Company, fees for facilities services, fees for company secretary services, fees for legal and auditing services, insurance premiums, printing, reporting and publishing expenses, including the cost of advertising and/or preparing and printing of the prospectuses, product key

AN-CAL-02156-E

^{*}The website has not been reviewed by the SFC.* The website has not been reviewed by the SFC.



facts statements, explanatory memoranda or registration statements, investment research fees, taxes or governmental or supervisory charges, all other operating expenses, including the cost of buying and selling assets, interest, bank charges and brokerage commissions, postage, telephone, telex, telefax message and facsimile (or other similar means of communication). The Company and/or the Administrative Agent, as appropriate, may calculate administrative and other expenses of a regular or recurring nature on an estimated figure for yearly or other periods in advance, and may accrue the same in equal proportions over any such period."

3. Other updates

The Explanatory Memorandum shall be updated to reflect the below:

(a) The third paragraph under the sub-section headed "ANTI-MONEY LAUNDERING AND COUNTER-TERRORIST FINANCING LEGISLATION" in the section headed "ADDITIONAL INFORMATION" shall be amended as follows (with revisions in mark-up):

"The Management Company reserves the right to ask at any time for additional information and documentary evidence, such as updated identity documentation, source of funds and origin of wealth, as may be required in higher risk scenarios or to comply with any applicable laws and regulations, including applicable Luxembourg regulations on the prevention of the use of the financial sector for money laundering purposes. In case of delay or failure to provide such information and/or documentary evidence, the Management Company may delay or reject the processing of purchase or sale instructions, or any other transaction. The Management Company may also delay or suspend the payment of dividends until relevant and satisfactory information and/or documentation is received. In addition, the Management Company reserves the right to stop the payment of any commissions and/or ultimately terminate the business relationship with sub-distributors, intermediaries, brokers/dealers and/or professional investors after reasonable attempts from the Management Company to obtain the missing or updated documentation requested from such sub-distributors, intermediaries, brokers/dealers and/or professional investors in line with applicable laws and regulations, thus preventing the Management Company from fulfilling its anti-money laundering and counter-terrorism financing obligations. Neither the Company nor the Management Company have any liability for delays or failure to process deals as a result of the Investor providing no or only incomplete information and/or documentary evidence."

- (b) Update to the conducting officers of the Management Company; and
- (c) Other miscellaneous, administrative and/or clarificatory updates.

The changes set out above do not amount to a material change to the Underlying Funds. There is no material change or increase in the overall risk profiles of any of the Underlying Funds following the above changes. Further, the above changes do not have a material adverse impact on Investors' rights or interests (including changes that may limit Investors' ability in exercising their rights), and the above changes are not expected to give rise to any change in the fee level or fee structure of any of the Underlying Funds.

Any costs and/or expenses incurred in connection with the above changes shall be borne by the Management Company, other than the cost of publishing letters, which is estimated to be approximately HKD120,000 and which shall be charged and allocated to the Underlying Funds based on the pro rata share of the Net Asset Value of the Underlying Funds.

The Explanatory Memorandum shall be updated to reflect the above changes in due course. An updated version of the Explanatory Memorandum shall be available for download from the Hong Kong Representative of FTIF's website at www.franklintempleton.com.hk^{*} and it will also be made available at the office of the Hong Kong Representative of FTIF in due course.

^{*} The website has not been reviewed by the SFC.



What does this mean to you?

If you wish to continue to invest in the Investment Choice(s) after considering the changes outlined above, you will not need to take any action. However, if you do not wish to maintain your investment in the Investment Choice(s), you may switch your existing holdings or redirect your future contribution allocations to alternative investment choice(s) by submitting an instruction to us, free of charge.

We recommend that you contact your licensed insurance intermediary in the first instance, who will be able to advise you of the alternative investment choice(s). For information on the fees and charges and the respective risk factors of our range of investment choices, please refer to the product brochure of the respective Schemes and the offering documents of the underlying funds made available by us upon request.

If you have any questions about this letter or your investment in the investment choice(s), please contact your licensed insurance intermediary, or you can call our customer care hotline at +852 3405 7150 or email us at helppoint.hk@hk.zurich.com and we will be happy to help.

Yours faithfully,

Zurich International Life Limited (a company incorporated in the Isle of Man with limited liability)

Note: Please note investments involve risks. The value of any investment and the income from it can fall as a result of market and currency fluctuations and you could get back less than the amount originally invested.



有關富蘭克林鄧普頓投資基金(「FTIF」)及該等相關基金(定義見下文)之變更

蘇黎世國際人壽保險有限公司 (於人島註冊成立之有限公司)

> 香港港島東華蘭路18號 港島東中心25-26樓

網址:www.zurich.com.hk

蘇黎世國際人壽保險有限公司是人島 Financial Services Authority所認可· 提供人壽保險、投資及保障產品。

於人島的註冊號碼為20126C。

註冊辦事處: Zurich House, Isle of Man Business Park, Douglas, Isle of Man, IM2 2QZ, British Isles 此乃重要函件、務請您即時垂注。您如對本函件的內容有任何疑問、請尋求專業意見。

我們就此函件所轉載資料的準確性承擔全部責任。除非另有訂明·否則本函件所載詞彙應與 FTIF日期為2023年4月的基金說明書(經不時修訂)(「**基金說明書**」)所載者具有相同涵 義。

親愛的客戶:

我們謹此致函通知您有關FTIF及該等相關基金的變更。您已投資於該等相關基金相應的至少一個投資選擇,其列於下表「受影響的投資選擇」中「投資選擇的名稱及代碼」一欄。

受影響的投資選擇

投資選擇(各稱為「該投資選擇」,統稱為「該等投資選擇」	相應的相關基金(各稱為「該 相關基金」,統稱為「該等相 問基金」,統稱	適用計劃(「計 劃」)
擇」)的名稱及代碼 蘇黎世國際富蘭克林美國政府 基金(代碼:TCUSD) 蘇黎世國際鄧普頓新興四強基 金(代碼:TFUSD) 蘇黎世國際鄧普頓新興市場基 金(代碼:TBUSD) 蘇黎世國際鄧普頓環球小型公	關基金」)名稱 富蘭克林鄧普頓投資基金 - 富 蘭克林美國政府基金 富蘭克林鄧普頓投資基金 - 鄧 普頓新興四強基金 富蘭克林鄧普頓投資基金 - 鄧 普頓新興市場基金 富蘭克林鄧普頓投資基金 - 鄧	 環球置業國際按揭計劃 「樂安閑」計劃 「樂安閑」Ⅲ 卓越精英國際投資計劃 至尊國際儲蓄投資 豐盛人生
司基金(代碼:TAUSD) 蘇黎世國際鄧普頓環球總收益 基金(代碼:TDUSD)	普頓環球小型公司基金 富蘭克林鄧普頓投資基金 - 鄧 普頓環球總收益基金	● 豊盛八王 ● 豐盛人生退休計劃
蘇黎世國際富蘭克林黃金及貴金屬基金(代碼:6CUSD) 蘇黎世國際富蘭克林中東北非美元基金(代碼:GCUSD)	富蘭克林鄧普頓投資基金 - 富蘭克林黃金及貴金屬基金 富蘭克林鄧普頓投資基金 - 富蘭克林中東北非基金	「樂安閑」計劃「樂安閑」Ⅲ卓越精英國際投資計劃
蘇黎世國際富蘭克林互惠環球探索基金(代碼:R2USD) 蘇黎世國際鄧普頓亞洲債券基金(代碼:4QUSD) 蘇黎世國際鄧普頓環球債券基金(代碼:TEUSD)	富蘭克林鄧普頓投資基金 - 富蘭克林互惠環球探索基金 富蘭克林鄧普頓投資基金 - 鄧普頓亞洲債券基金 富蘭克林鄧普頓投資基金 - 鄧普頓環球債券基金	● 至尊國際儲蓄投資 ● 豐盛人生 ● 豐盛人生退休計劃



富蘭克林鄧普頓投資基金 - 富蘭克林生物科技新領域基金(代碼: USDTC)	富蘭克林鄧普頓投資基金 - 富蘭克林生物科技新領域基金	國際創富計劃景緻人生翱翔人生
富蘭克林鄧普頓投資基金 - 富蘭克林黃金及貴金屬基金(歐元)(代碼: HSEUR) 富蘭克林鄧普頓投資基金 - 富蘭克林黃金及貴金屬基金(美	富蘭克林鄧普頓投資基金 - 富 蘭克林黃金及貴金屬基金	
元)(代碼:6BUSD) 富蘭克林鄧普頓投資基金 - 富 蘭克林印度基金 (代碼:FWUSD)	富蘭克林鄧普頓投資基金 - 富蘭克林印度基金	
富蘭克林鄧普頓投資基金 - 富蘭克林中東北非基金 (美元) (代碼:GDUSD)	富蘭克林鄧普頓投資基金 - 富蘭克林中東北非基金	
富蘭克林鄧普頓投資基金 - 富蘭克林互惠歐洲基金 (代碼:FVUSD)	富蘭克林鄧普頓投資基金 - 富蘭克林互惠歐洲基金	
富蘭克林鄧普頓投資基金 - 富蘭克林互惠環球探索基金 (代碼: Q2USD) 富蘭克林鄧普頓投資基金 - 富	富蘭克林鄧普頓投資基金 - 富蘭克林互惠環球探索基金 富蘭克林鄧普頓投資基金 - 富	
蘭克林互惠美國價值基金 (代碼:KYUSD) 富蘭克林鄧普頓投資基金-富	蘭克林互惠美國價值基金 富蘭克林鄧普頓投資基金 - 富	
蘭克林美國政府基金 (代碼:ZVUSD) 富蘭克林鄧普頓投資基金 - 鄧	蘭克林美國政府基金	
普頓亞洲債券基金 (代碼:4PUSD) 富蘭克林鄧普頓投資基金-鄧	普頓亞洲債券基金 富蘭克林鄧普頓投資基金 - 鄧	
普頓亞洲增長基金(美元) (代碼:KOUSD) 富蘭克林鄧普頓投資基金 - 鄧	普頓亞洲增長基金 富蘭克林鄧普頓投資基金 - 鄧	
普頓新興市場基金 (代碼:MMUSD) 富蘭克林鄧普頓投資基金 - 鄧	普頓新興市場基金 富蘭克林鄧普頓投資基金 - 鄧	
普頓環球小型公司基金 (代碼:MLUSD) 富蘭克林鄧普頓投資基金-鄧	普頓環球小型公司基金 富蘭克林鄧普頓投資基金 - 鄧	
普頓環球總收益基金 (代碼:PDUSD)	普頓環球總收益基金 	

修訂事項

FTIF的香港代表富蘭克林鄧普頓投資(亞洲)有限公司已通知我們以下變更·相關變更自2023年8月27日起生效。

1. 更新富蘭克林鄧普頓投資基金 - 富蘭克林生物科技新領域基金、富蘭克林鄧普頓投資基金 - 鄧普頓亞洲債券基金及富蘭克林鄧普頓投資基金 - 鄧普頓環球債券基金的合約前披露

該等相關基金的合約前披露應作出更新,以反映根據委員會授權法規(歐盟)第2023/363號規定使用的最新模板,其中包括新增兩個有關該等相關基金投資於符合歐盟分類條例的化石氣體及/或核能相關活動的問題。

此外,該相關基金的合約前披露應作出修訂,以反映以下重要變更:



(a) 富蘭克林鄧普頓投資基金 - 富蘭克林生物科技新領域基金的合約前披露中標題為「*此金融產品遵循什麼投資策略?*」的問題應作出修訂,以將「核武器」納入特定ESG排除項之一。

更新後的該等相關基金雙語合約前披露可於FTIF香港代表的網站

https://franklintempletonprod.widen.net/s/jqdp5bk5xt/ftif-sfdr-pre-contractual-disclosure-annexes_hk_en*(英文版本)及

https://franklintempletonprod.widen.net/s/hv85nxn6tb/ftif-sfdr-pre-contractual-disclosure-annexes_hk_cn* (繁 體中文版本)下載,且其亦可於FTIF的香港代表辦事處取得。

2. FTIF的估值政策之更新

為澄清在不同國家獲得和維持註冊所產生的費用以及設施服務與公司秘書服務的費用均由FTIF承擔·基金説明書内標題為「其他資料」一節下的「估值」一分節中有關總負債的段落内的第(e)項應作出以下更新(修訂已標明):

「(e)本公司任何類型及性質之所有其他債務,但於本公司股份導致的負債除外。在釐定該等債務金額時,本公司應考慮本公司所有應付的相關費用,包括成立費用、賬戶費用及開支、應付予管理公司的各種服務費用、有關投資經理及/或投資顧問、存管人及當地支付代理、註冊地永久代表以及在不同國家獲得和維持註冊所產生的費用及本公司僱用的任何其他代理人所提供之服務的費用、設施服務費用、公司秘書服務費用、法律及核數費用、保險金、印刷、報告及發行費用(包括刊登及/或製作與印刷招股說明書、產品資料概要、解釋說明書或登記聲明的費用)、投資研究費用、稅項或政府或監管收費及所有其他營運開支(包括資產的買賣成本、利息、銀行收費及經紀佣金、郵遞、電話、電報、電傳信息及傳真(或其他相似通訊方式)費用)。本公司及/或行政代理(如適用)可預先計算每年或其他期間定期或經常性行政費用及其他費用之預測金額,並可於任何該等期間按相等比例累計該等費用。」

3. 其他更新

基金説明書應作出更新,以反映以下變更:

(a) 標題為「其他資料」一節下的「反洗錢及反恐怖主義融資法律」一分節的第三段應作出以下修訂(修訂已標明):

「在較高風險情況下或為遵守任何適用的法律法規(包括適用的盧森堡關於防止將金融部門用於洗錢目的之法規),管理公司保留隨時要求提供額外資料及文件證明的權利,例如更新的身份證明文件、資金來源及財富來源。如果延遲或未能提供該等資料及/或文件證明,管理公司可能會延遲或拒絕處理認購或出售指令或任何其他交易。管理公司也可以延遲或暫停支付股息,直至收到相關足以符合要求的資料及/或文件。此外,在管理公司根據適用的法律及法規合理嘗試向次級分銷商、中介人、經紀/交易商及/或專業投資者獲取缺失或更新資料後,因此妨礙管理公司履行其反洗錢及反恐融資義務,管理公司保留權利停止支付任何佣金及/或最終終止與該等次級分銷商、中介人、經紀/交易商及/或專業投資者的業務關係。對於因投資者未能提供或僅提供不完整的資料及/或文件證明而導致的延遲或未能處理交易,本公司及管理公司均不承擔任何責任。」

- (b) 管理公司的營運總監之更新;
- (c) 其他雜項、行政及/或澄清更新。

上述變更並不構成對該等相關基金的重大變更。上述變更之後,任何該等相關基金的整體風險概況並無重大變更 或增加。此外,上述變更不會對投資者的權利或利益產生重大不利影響(包括可能限制投資者行使其權利的變 更),且上述變更預計不會導致任何該等相關基金的收費水平或收費結構發生任何變化。

因上述變更而產生的任何費用及 / 或開支應由管理公司承擔·刊發信件的費用除外·該費用預計約為120,000港元·應由該等相關基金按該等相關基金股份的資產淨值比例承擔。

ZIL-CAN-CAL-02156-ET-0124

^{*}此網站未經證監會審核。



基金説明書應適時更新,以反映上述變更。基金說明書的更新版本可於FTIF的香港代表網站www.franklintempleton.com.hk*下載,並亦適時可於FTIF的香港代表辦事處提供。

對您產生的影響

如您在考慮上述變更後仍繼續投資於該等投資選擇,則無需就此修訂作出任何行動。倘若您不欲繼續投資於該等投資選擇,可向本公司遞交轉換現有投資或重新指定未來供款分配至其他投資選擇的指示,費用全免。

我們建議您首先諮詢您的持牌保險中介人,以取得其他投資選擇的建議。有關本公司投資選擇(包括費用及收費,以及其相關風險因素)的詳情,請參閱相關計劃的產品介紹冊及相關基金的銷售文件,本公司會應要求提供上述銷售文件。

如您對本函件或投資選擇中的投資有任何疑問,請聯絡您的持牌保險中介人。您亦可致電+852 3405 7150或電郵至helppoint.hk@hk.zurich.com聯絡客戶服務部,我們將樂意為您效勞。

蘇黎世國際人壽保險有限公司 (於人島註冊成立之有限公司) 2024年1月12日

註:投資涉及風險,您的投資價值及收益可因市場及貨幣波動而下跌,有可能導致您不能取回所有投資款項。

ZIL-CAN-CAL-02156-ET-0124

^{*} 此網站未經證監會審核。